12 assets in Pancreatic Adenosquamous Carcinoma

Therapeutic assets addressing Pancreatic Adenosquamous Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fluorouracilum Pancreatic Adenosquamous Carcinoma	Revolution Medicines, Inc.	P3	BB (64)
Irinotecan Pancreatic Adenosquamous Carcinoma	Revolution Medicines, Inc.	P3	BB (64)
Daraxonrasib Pancreatic Adenosquamous Carcinoma	Revolution Medicines, Inc.	P3	B (60)
Zoldonrasib Pancreatic Adenosquamous Carcinoma	Revolution Medicines, Inc.	P3	B (60)
Cis-Diamminedichloroplatinum Ii Pancreatic Adenosquamous Carcinoma	Alliance for Clinical Trials in Oncology	P2/3	B (57)
Minnelide Pancreatic Adenosquamous Carcinoma	National Cancer Institute (NCI)	P2	B (57)
Oxaliplatin Pancreatic Adenosquamous Carcinoma	Revolution Medicines, Inc.	P3	B (56)
Olaparib Pancreatic Adenosquamous Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Domvanalimab Pancreatic Adenosquamous Carcinoma	James Cleary, MD, PhD	P1/2	CCC (48)
Samuraciclib Pancreatic Adenosquamous Carcinoma	University Health Network, Toronto	P1/2	CCC (48)
Zimberelimab Pancreatic Adenosquamous Carcinoma	James Cleary, MD, PhD	P1/2	CCC (48)
Sotigalimab Pancreatic Adenosquamous Carcinoma	James Cleary, MD, PhD	P1/2	CC (45)